The secret to the survival abilities of these cells has been unclear. But in a paradoxical discovery, a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has found that a tumor suppressor protein known as PML appears to be the factor that enables LICs to maintain their quiescence – the inert state that protects them from being destroyed by cancer therapies – and suggests that inhibition of PML is a promising target for new therapeutics.
Read the whole story here at the ecancer medical science website:
http://www.ecancermedicalscience.com/news-insider-news.asp?itemId=172
No comments:
Post a Comment